A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy.

Kristen K. Ciombor, Tanios Bekaii‐Saab, Joleen M. Hubbard et al.|Journal of Clinical Oncology|2015

Cited by 6